氯化锶,Sr-89 | 38270-90-5

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱土金属盐
• 中文名称: 氯化锶,Sr-89
• 英文名称: Strontium Chloride Sr-89
• 英文别名: strontium-89(2+);dichloride
• CAS: 38270-90-5
• 化学式: Cl2Sr
• 分子量: 159.81
• InChiKey: AHBGXTDRMVNFER-FCHARDOESA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -6.37
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

ADMET

代谢

锶可以与通常与钙结合的成分相互作用，包括羟基磷灰石（矿化骨骼的主要成分）、钙结合蛋白或钙传输蛋白。它可以与不同的无机阴离子如碳酸根、柠檬酸根、磷酸根、羧酸根或乳酸根形成络合物。

Strontium can interact with components than normally bind to calcium, including hydroxyapatite (main component of mineralized bone), calcium-binding or calcium-transport proteins. It can form complexes with different inorganic anions like carbonate, citrate, phosphate, carboxylic acid or lactate.

来源:DrugBank

毒理性

• 在妊娠和哺乳期间的影响

哺育期使用总结：本记录中的信息指的是将锶-89作为治疗剂的使用。目前没有关于在哺乳期间使用锶-89治疗的信息。据估计，大约9%的锶会从母体血液中进入母乳，对于另一种锶同位素，锶-90而言。[1] 由于锶可以替代婴儿骨骼中的钙，制造商和专家意见建议在接受氯化锶-89治疗前停止哺乳。[2] 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:IInformation in this record refers to the use of strontium 89 as a therapeutic agent. No information is available on the therapeutic use of strontium 89 during breastfeeding. It has been estimated that about 9% of the strontium in the maternal bloodstream reaches breastmilk for another strontium isotope, strontium 90.[1] Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives strontium 89 chloride.[2] ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

毒理性

• 蛋白质结合

在一些对污染水的研究中，已经显示出锶能够与血浆蛋白结合。在人类血浆的研究中，通过超滤法可以回收大约45-60%的摄入锶，而其他研究证实了30-40%的蛋白结合率。

In some studies performed in polluted water, it was showed that strontium is able to bind to plasma proteins. In human plasma studies, it has been shown a possible recovery of 45-60% of administered strontium by ultrafiltration, while other studies confirm a protein binding of 30-40%.

来源:DrugBank

吸收、分配和排泄

• 吸收

静脉注射后，氯化锶89的行为类似于它的钙类似物。它从血液中迅速清除并选择性地定位于骨矿物质上，尤其是在成骨区域，它可以在那里保留大约14天。

Following intravenous injection, strontium chloride 89 behaves like its calcium analog. It clears rapidly from the blood stream and selectively gets localized on the bone mineral, preferentially in zones of osteogenesis, where it can stay retained for about 14 days.

来源:DrugBank

吸收、分配和排泄

• 消除途径

注射后前两天主要通过尿液排出，剩余部分通过粪便排出。尿液中排出的百分比可能会因骨骼损伤的存在而有所不同。粪便中存在氯化锶89表明它被吸收进入胃肠系统，可能是通过胆汁或从血浆中吸收。

The elimination is done mainly by urinary excretion greatly in the two first days after injection. The rest of the elimination route is found in faeces. The percentage of urinary excretion may vary depending on the presence of bone lesions. The presence of strontium chloride 89 in faeces suggests an absorption into the gastrointestinal tract either by the bile or from the plasma.

来源:DrugBank

吸收、分配和排泄

• 分布容积

关于氯化锶89不同给药途径的药代动力学已经进行了几项研究。数值有所不同，但大致介于40-67升之间。

There have been several studies regarding the pharmacokinetics of different administration routes of strontium chloride 89. The values are different but it ranges between 40-67L.

来源:DrugBank

吸收、分配和排泄

• 清除

氯化锶89主要通过尿液以3:1的比例清除，与粪便排泄相比。总药物清除速度较慢，使其具有较长的半衰期。

Strontium chloride 89 is mainly cleared by urine on a 3:1 ratio compared with fecal excretion. The total drug clearance can be slow, giving it a long half-life.

来源:DrugBank